Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aleglitazar + metformin
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aleglitazar + metformin is an investigational combination therapy for type 2 diabetes mellitus. Aleglitazar is a dual agonist of peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ), designed to improve both lipid and glucose metabolism, thereby addressing dyslipidemia and insulin resistance in diabetes. Metformin, a biguanide, decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity. The combination has been studied in patients with type 2 diabetes inadequately controlled on metformin alone to further improve glycemic control and cardiometabolic risk factors[1][3][4][6].
02
Targets
ND1 (Mitochondrial electron transport chain complex I)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on Aleglitazar + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aleglitazar + metformin.